Mirum Pharmaceuticals, INC 10-Q quarterly reports

Mirum Pharmaceuticals announces a significant increase in product sales and substantial R&D investment in its Q1 2026 results.

Mirum Pharmaceuticals, Inc. reported a net income of $2.9 million for the third quarter of 2025, driven by significant increases in product sales, particularly Livmarli and Bile Acid Medicines.

Mirum Pharmaceuticals reports significant revenue growth and a substantial reduction in net loss for Q2 2025, driven by strong product sales and pipeline advancements.

Mirum Pharmaceuticals' Q1 2025 revenue increased significantly, driven by strong sales of Livmarli and Bile Acid Medicines, while the company continues to invest in its pipeline and commercial infrastructure.

Mirum Pharmaceuticals saw a significant increase in product sales in the third quarter of 2024, driven by both Livmarli and Bile Acid Medicines, though the company continues to operate at a net loss.

Mirum Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of Livmarli and the newly acquired Bile Acid Medicines.

Mirum Pharmaceuticals saw a significant increase in revenue in the first quarter of 2024, primarily driven by sales of Livmarli and the newly acquired Bile Acid Medicines.